Platinum-Pemetrexed

Platinum-pemetrexed is a two-drug chemotherapy combination, a platinum-based drug (usually cisplatin or carboplatin) given together with pemetrexed (brand name Alimta), that has been the standard first-line chemotherapy for pleural mesothelioma for two decades. The drugs are infused intravenously, typically every three weeks for four to six cycles. The combination works by damaging cancer cell DNA and blocking enzymes the cancer needs to make new DNA.

Origin

Pemetrexed was developed by Eli Lilly in the 1990s and approved by the FDA in 2004 for malignant pleural mesothelioma based on the pivotal Vogelzang trial (EMPHACIS study), which showed that adding pemetrexed to cisplatin improved median survival from about 9 to 12 months compared to cisplatin alone. It became the first chemotherapy regimen ever approved specifically for mesothelioma.

Significance in Asbestos Context

For many mesothelioma patients, platinum-pemetrexed is the first systemic treatment offered after diagnosis, either alone or in combination with surgery and radiation (multimodal therapy) or with the antibody bevacizumab. Since 2020, immunotherapy (nivolumab plus ipilimumab) has become an alternative first-line option, particularly for non-epithelioid mesothelioma, so patients should ask their oncologist which approach fits their specific cell type and overall health. Medical records documenting this regimen (including infusion dates, cycles completed, response on imaging, and side effects) are important parts of a legal claim because they establish the diagnosis, the seriousness of treatment, and damages such as pain, suffering, and medical costs.

Example Sentence

After his pleural mesothelioma diagnosis, his oncologist recommended six cycles of platinum-pemetrexed before reassessing whether surgery was still an option.

Related Terms

Mesothelioma, Cisplatin, Carboplatin, Bevacizumab, Immunotherapy, Multimodal Therapy

Notes

• Ask your oncologist whether cisplatin or carboplatin is being used. Carboplatin is often substituted for patients with kidney problems, hearing loss, or who are older or frailer, and it has a different side-effect profile.
• Pemetrexed requires daily folic acid and periodic vitamin B12 injections starting before the first dose to reduce toxicity; confirm these supplements are prescribed.
• Keep copies of all infusion records, imaging reports (CT or PET scans showing response), and toxicity notes. These document both your treatment burden and your response, and are relevant to legal damages.
• Ask whether you are a candidate for first-line immunotherapy (nivolumab/ipilimumab) instead of or in addition to chemotherapy, especially if your tumor is sarcomatoid or biphasic.
• Inquire about clinical trials that may combine platinum-pemetrexed with newer agents; major mesothelioma centers often have trials not available locally.